This page shows the latest bevacizumab news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s biosimilars business grew by 34% to $575m, driven by the launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab), as well as continued growth from Retacrit (epoetin) in the
or without bevacizumab based on data from the phase 3 KEYNOTE-826 trial.
These savings derived mainly from trastuzumab and bevacizumab to treat a range of cancers, infliximab for autoimmune diseases, and pegfilgrastim to treat chemotherapy-related neutropenia, says the report.
cancer, two-thirds of which had previously received Avastin (bevacizumab). ... Merck announced that its pivotal phase 3 KEYNOTE-826 trial showed that Keytruda (pembrolizumab) plus chemotherapy with or without bevacizumab reduced the risk of death by
The phase 3 KEYNOTE-826 trial evaluated Keytruda (pembrolizumab) in combination with platinum-based chemotherapy with or without Roche’s Avastin (bevacizumab) for the first-line treatment of adults with persistent,
treatments Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).
More from news
Approximately 21 fully matching, plus 191 partially matching documents found.
Roche has already chalked up the first successes pairing Tecentriq (atezolizumab) with its veteran anticancer antibody Avastin (bevacizumab) in first-line NSCLC and kidney cancer, with additional trials of the duo
Roche instituted similar principles in the promotion of its cancer drug, Avastin (bevacizumab), which works by finding and blocking the blood supply feeding malignant tumors.
Still in Japan, a week later AZ agreed a joint venture with Fujifilm Kyowa Kirin Biologics for the development and commercialisation of a biosimilar version of bevacizumab (Avastin) in phase I
NA. Bevacizumab. Biocad. Russia. BCD-021. Clinical. NSCLC: Ph III started in Oct 2012.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
According to their study, Black patients were significantly less likely than white patients to show short-term visual improvement after being given bevacizumab (Avastin), a common treatment used in the
These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...